General Information |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2024-06-30 |
| End date (estimated) |
2031-12-31 |
| Clinical feature |
| Label |
Acute Myeloid Leukemia |
| Link |
http://purl.obolibrary.org/obo/NCIT_C3171 |
| Description |
A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification). |
|
Administrative Information |
| NCT number |
NCT06441084 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06441084 |
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT06441084 |
| Sponsors |
Nuwacell Biotechnologies Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
15 |
